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Introduction: The increasing number of targeted therapies, together with a deeper understanding of cancer
genetics and drug response, have prompted major healthcare centers to implement personalized treatment
approaches relying on high-throughput tumor DNA sequencing. However, the optimal way to implement this
transformative methodology is not yet clear. Current assays may miss important clinical information such as the
mutation allelic fraction, the presence of sub-clones or chromosomal rearrangements, or the distinction between
inherited variants and somatic mutations. Here, we present the evaluation of ultra-deep targeted sequencing
(UDT-Seq) to generate and interpret the molecular profile of 38 breast cancer patients from two academic medical
centers.
Methods: We sequenced 47 genes in matched germline and tumor DNA samples from 38 breast cancer patients.
The selected genes, or the pathways they belong to, can be targeted by drugs or are important in familial cancer
risk or drug metabolism.
Results: Relying on the added value of sequencing matched tumor and germline DNA and using a dedicated
analysis, UDT-Seq has a high sensitivity to identify mutations in tumors with low malignant cell content.
Applying UDT-Seq to matched tumor and germline specimens from the 38 patients resulted in a proposal for
at least one targeted therapy for 22 patients, the identification of tumor sub-clones in 3 patients, the
suggestion of potential adverse drug effects in 3 patients and a recommendation for genetic counseling for
2 patients.
Conclusion: Overall our study highlights the additional benefits of a sequencing strategy, which includes
germline DNA and is optimized for heterogeneous tumor tissues.Introduction
The use of highly effective targeted therapies in cancer
frequently depends on the specific mutational profile of
the tumor. As an increasing number of targeted therapies
become available, determining the comprehensive genetic
profile of a tumor is critical in understanding the response
to targeted drugs for cancer treatment. Indeed, this gen-
etic profile can help predict sensitivity or resistance to* Correspondence: oharismendy@ucsd.edu; hantoncu@uci.edu;
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distribution, and reproduction in any mediumparticular therapies and can therefore offer new, tailored
treatment options to patients with late-stage or recurrent
disease. In breast cancer, for example, trastuzumab has
been used for Her2 amplified or overexpressing breast
cancer. Notably, this strategy may suggest the use of a
drug indicated for another anatomic cancer type, or the
use of an investigational drug. Measuring the true clinical
benefit of this tailored strategy is difficult, however, be-
cause targeted therapy frequently leads to drug resistance,
the mechanisms of which are often not well understood.
Nevertheless, this area of research is developing rapidly
and some preliminary studies matching therapy to the
tumor mutational profile across many clinical trials show
an improved response rate [1].ntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Harismendy et al. Breast Cancer Research 2013, 15:R115 Page 2 of 12
http://breast-cancer-research.com/content/15/6/R115Traditionally, several types of molecular assays are
available to identify somatic DNA mutations in tumors.
Such assays analyze single positions, single exons, or
whole genes using mass spectrometry [2], allele-specific
polymerase chain reaction (PCR) [3] or Sanger sequen-
cing. These assays are, however, limited in scope – look-
ing only at specific genes or mutations – and limited in
sensitivity – usually dependent on the fraction of tumor
cells contained in the tissue specimen. More recently,
high-throughput sequencing of candidate genes has ex-
tended the breadth and sensitivity of this approach,
overcoming some of these drawbacks [4-7]. Some major
clinical centers are now starting to use more compre-
hensive molecular profiling in clinical care. However,
these assays differ with regards to breadth (number of
genes), depth (number of independent DNA molecules
sampled) and design – selection of the genes or inclu-
sion of a matched germline control. As a consequence,
the clinical utility may vary. The Cancer Genome Atlas
(TCGA) [8], a consortium focused on research and dis-
covery, sequenced the entire exome of tumors but at
limited coverage depth, rejecting specimens with less
than 60% cellularity and preventing the reliable identifica-
tion of subclonal mutations. More targeted commercial
assays such as Foundation One (Foundation Medicine,
Cambridge, MA) may generate increased coverage depth
of a smaller set of genes but do not always report the mu-
tant allelic fraction [9]. Such diagnostic services also omit
the comparison with a matched germline control, which is
essential to increase the analytical sensitivity and distin-
guish between inherited variants and somatic mutations.
Ultra-deep targeted sequencing (UDT-Seq) [5,10] of
matched tumor–germline specimens has not yet been
evaluated in a clinical setting. The sequencing of matched
tumor–germline samples is crucial to distinguish somatic
mutations from sequencing artifacts; it is also critical to
establish with certainty that a variant identified in the
tumor is somatic rather than inherited since filtering
against polymorphism databases can eliminate real muta-
tions [11]. In the absence of a matched germline DNA se-
quence, the misinterpretation of an inherited variant for a
somatic mutation could potentially prevent a patient from
getting appropriate genetic counseling. Additionally, inhe-
rited variation in metabolism genes such as DPYD or
CYP2D6 has been associated with 5-fluorouracil toxicity
and possibly tamoxifen efficacy [12], respectively, and, al-
though the variants are rare, a more systematic clinical
screening would provide important benefits. The simul-
taneous sequencing of the germline DNA along with the
tumor DNA therefore offers technical advantages to iden-
tify somatic mutations at low allelic fraction and increases
the opportunity to identify actionable inherited variants.
Here, we evaluate a targeted sequencing assay for its use
in a cancer clinical setting. Specifically, we performedUDT-Seq of 47 genes that are clinically actionable or im-
portant for patient care. We show that potentially import-
ant information is gained by sequencing at high depth,
including identification of subclonal mutations. Additional
information is also gained from the sequencing of matched
germline DNA and from the inference of tumor DNA copy
number alterations. We therefore demonstrate that in com-
parison with other high-throughput sequencing methods,
UDT-Seq of matched tumor–germline DNA used in a clin-
ical setting generates more potentially actionable findings
for a greater number of patients.
Methods
Clinical specimens
All University of California, San Diego and University of
California, Irvine patients were consented in accordance
with the protocols approved by their respective Institutional
Review Board of the university (Table S1 in Additional file 1
and Additional file 2). Snap-frozen tissue samples were
subjected to mechanical pulverization, followed by disrup-
tion of the tissue in lysis buffer and DNA/RNA extraction
using AllPrep DNA extraction kits (Qiagen GmbH, Hilden,
Germany) according to the manufacturer’s recommenda-
tion. Germline DNA was extracted from blood clots using
Qiagen Clotspin Baskets and DNA QIAmp DNA Blood
maxi kits (Qiagen Inc., Valencia, CA, USA) and from
saliva samples according to the respective manufac-
turer’s protocol.
Data generation
The data were generated according to our published UDT-
Seq method [5,10]. Briefly, the genomic DNA samples
were fragmented to an average size of 3 kb. To prepare the
input DNA template mixture for targeted amplification,
1.5 μg of the purified genomic DNA fragmentation reac-
tion was added to 9.4 μl of 10× High-Fidelity Buffer
(11304–029; Invitrogen (Carlsbad, CA, USA)), 2.5 μl of
50 mMMgSO4, 2.5 μl of 10 mM dNTP, 7.2 μl of 4 M Beta-
ine, 7.2 μl RDT Droplet Stabilizer, 3.6 μl dimethyl sulfoxide
and 1.4 μl of 5 units/μl Platinum High-Fidelity Taq (Invi-
trogen), and the samples were brought to a final volume of
50 μl with nuclease-free water. The primer droplets (Table
S2 in Additional file 1 and Additional file 2) were merged
with the sample droplets on the RDT1000 (RainDance
Technologies (Billerica, MA, USA)).
The PCR reactions were carried out as follows: initial
denaturation at 94°C for 2 minutes; 55 cycles at 94°C for
30 seconds, 54°C for 30 seconds and 68°C for 60 seconds;
and final extension at 68°C for 10 minutes, followed by a
4°C hold. After breaking the emulsion and purification
of the amplicons, the samples were subjected to the sec-
ondary PCR using 0.5 μM final concentration of a uni-
versal forward primer and an index-specific reverse
primer (Table S3 in Additional file 1). Samples were
Figure 1 Histology examination. For each sample, the proportion
of necrosis, immune cells, stromal cells, in situ tumor and invasive
tumor is indicated.
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nutes; 10 cycles at 94°C for 30 seconds, 56°C for 30 sec-
onds and 68°C for 1 minute; and final extension at 68°C
for 10 minutes, followed by a 4°C hold. The purified amp-
lified library was then analyzed on an Agilent Bioanalyzer to
quantify final amplicon yield and pooled in equimolar
amounts. The pool was loaded at between 8 and 11 pM (de-
pending on the run) and sequenced on the Illumina (San
Diego, CA, USA) MiSeq sequencing instrument for 2 ×
150 cycles using custom sequencing primers (Table S3 in
Additional file 1). The resulting reads were deconvoluted
based on their index sequence. The raw reads are publi-
cally available through the Short Reads Archive at the
NCBI: SRA067610 and SRA067611. The libraries were se-
quenced to an average of 3.1 million 151 bp long paired-
end reads per sample (Table S4 in Additional file 1).
Data analysis
Mutascope
The analysis was performed using Mutascope capable of de-
tecting mutations at 1% allelic fraction with high sensitivity
[10]. We first identified potential false positive variants
(module makeBlackList). We then aligned the reads to the
human genome (modules runBWA, refinement, groupRea-
lign, and xpileup). Mutascope calculates the error rate for
each position/substitution/strand group (module calcEr-
rorRates) at positions that are not database of single nu-
cleotide polymorphisms (dbSNP) positions and uses this
to calculate the binomial probability of mutations in the
tumor (module callSomatic) distinguishing somatic from
germline using an additional Fisher exact test. Finally,
likely false positive mutations were filtered out using
coverage bias, read-group bias, ambiguity of alternate al-
lele, mapping quality, alternate allele quality, proximity to
an indel, or to a homopolymer.
Copy number alterations
The average number of reads per gene was calculated for
each sample sequenced. We then computed the mean and
standard deviation of the normalized coverage in the germ-
line DNA for each patient at each gene. The significance of
amplification or deletion of a specific gene in the tumor
DNA was estimated by comparing the tumor normalized
coverage to the distribution of normal normalized coverage
at this gene for all patients, using the R function pnorm. Fol-
lowing the Bonferroni correction for multiple testing, we re-
ported amplifications (logR >1) and deletion (logR <−1)
events with P <5.6 × 10–6 (Table S5 in Additional file 1).
Variant annotation
Variants were queried against dbSNP135 to determine novel
or known variants. We next used snpEff [13] version 2.0.5
in combination with GATK VariantAnnotator (Broad Insti-
tute, Cambridge MA, USA), both with default parameters,to identify the different functional impacts on coding genes.
We enriched this annotation by cross-referencing the list of
variants to the dbNSFP database [14], which provides con-
servation (PhyloP), functional prediction (SIFT, PolyPhen
and MutationTaster), as well as Uniprot codon change infor-
mation. Finally, we annotated the variants for presence in
Catalogue of Somatic Mutations in Cancer v61 (Welcome
Trust Sanger Institute, Hinxton, UK) based on coordinate
and genotype. Notably, we used Catalogue of Somatic Muta-
tions in Cancer codon numbering when discordant number-
ing was reported between databases.
Results
We collected 38 tumors, including two lobular invasive car-
cinoma, 35 ductal invasive carcinoma (six of which showed
lobular features) and one Ductal Carcinoma In Situ. Not-
ably, four tumors had cellularity lower than 20% (Figure 1)
and six tumors were Her2-positive as determined by stand-
ard testing (Table S1 in Additional file 1 and Additional file
2). We assembled a panel of 47 genes to analyze these speci-
mens using UDT-Seq. The genes were selected for their
clinical importance or their relevance to breast cancer genet-
ics and treatment (Table 1). The coverage resulting from the
sequencing of the 1,736 amplicons from 38 pairs of tumor
DNA and germline DNA was deep (Table S4 in Additional
file 1; with an average of 1,481 reads per amplicon), sensitive
(with 92% of the bases covered at 500× or more) and highly
uniform (with an average of 92.6% of the bases within two-
fold of the mean) – in agreement with the published specifi-
cations of microdroplet PCR [5,10,15], which provides high-
quality data for clinical sequencing.
Chromosomal alterations
The precise allelic fraction measured at each sequenced
position by UDT-Seq can be reflective of the prevalence
















PIK3CA S, Y Y
PTEN S, G Y Y
BRAF S, Y Y
KRAS S, Y
EGFR S, Y Y
ALK S, Y Y Y
ERBB2 S, Y Y Y
JAK2 S, Y
PDGFRB S, Y









AKT1 S, Y Y
APC S, G
PIK3R1 S,




MET S, G Y Y
FGFR2 S, Y Y
ABL2 S,
BRCA2 S, G Y
CTNNB1 S,
ERBB4 S, Y








CYP2D6 P (tamoxifen (+/−))
CYP2C9 P (warfarin)
VKORC1 P (warfarin)
Table 1 Genes included in the breast cancer panel
sequenced by UDT-Seq (Continued)







FDA, Food and Drug Administration; UDT-Seq, ultra-deep targeted sequencing.
aS somatic mutations; G, germline cancer risk; P, pharmacogenetic risk;
R, reproductive significance.
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sult from chromosomal losses or gains. Therefore it is
important to first identify these chromosomal alterations
to interpret the mutations’ allelic fraction but also to re-
veal potential actionable events such as the amplification
of a targetable oncogene.
As shown previously, the distribution of the fractions
of reads per amplicon generated by UDT-Seq is highly
reproducible from sample to sample [5]. As a result, the
difference in coverage depth of an amplicon between
tumor and germline can be indicative of chromosome
copy number gains or losses. Indeed, we noticed that
five of the six samples determined by traditional
methods (immunohistochemistry or fluorescent in situ
hybridization) to have Her2 amplification show a higher
coverage depth at ERBB2 amplicons, the gene coding for
Her2 (Figure 2A). The immunohistochemistry or fluor-
escent in situ hybridization score is correlated with the
level of amplification determined by this approach (r2 =
0.70; Figure 2B). We also identified potential copy
number gains of ABL2, BRAF, FGFR2 and PIK3CA in
one sample, FGFR1 in two samples, as well as a loss
of FGFR1OP in one sample (Figure 2A; Table S5 in
Additional file 1). Despite the high coverage depth
generated, the low tumor cell content and overall level
of gene amplification in a sample can reduce the sensitivity
of this approach, as illustrated by a false negative Her2-
amplified sample, which had low in situ hybridization ratio
(2.8) and 50% tumor cell content. Nevertheless, this in-
ference of copy number alterations can identify bona-
fide actionable events.
The high depth of sequencing of both tumor and
germline also facilitates the identification of loss of hetero-
zygosity events, by measuring the allelic fraction of het-
erozygous polymorphisms in the tumor (Figure 2C,D).
This observed effect on allelic fraction is, however, a
combination of tumor purity and ploidy that is difficult
to separate using only ~150 germline variants per pa-
tient. We can summarize this instability using the stand-
ard deviation of the allelic fraction of the heterozygous
Figure 2 Somatic rearrangements. (A) Heatmap representing the average logR ratio of tumor/germline coverage depth observed on all
amplicons of a given gene (rows) in the sequenced samples (columns). Red, gains; blue, losses. Black frames indicate significant changes
(P <5.6 × 10–6). (B) The logR ratios of tumor/germline coverage depth of the Her2 gene correlate with the results of immunohistochemistry.
(C), (D) Scatterplot representing the allelic fraction of the germline variants in the germline DNA (x axis) and tumor DNA (y-axis) for tumors
showing a low (C) or high (D) level of chromosomal instability. The standard deviation of heterozygotes (SDH) score, calculated from the
standard deviation of the allelic fraction of heterozygous single nucleotide polymorphisms in the tumor, is indicated. (E) Distribution of SDH
scores in the sequenced cohort as a function of histological grade (x axis). Invasive lobular carcinoma (ILC; red) and invasive ductal carcinoma
(IDC) showing lobular features (orange) are indicated. (F) Cumulative fraction of tumors with high SDH score (y axis), at increasing tumor
cellularity (x axis). IHC, immunohistochemistry.
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(standard deviation of heterozygotes (SDH) score;
Figure 2E). The SDH score was correlated with the Not-
tingham grade (P <0.005, Student’s t test), indicating that
high-grade tumors have more chromosomal rearrange-
ments, especially for ductal carcinomas in situ. Similarly,
for highly cellular tumors, a high SDH score is indicative
of a high chromosomal instability. As expected, a higher
fraction of elevated SDH score was observed in high cellu-
larity samples (Figure 2F), indicating that chromosomal
instability is more difficult to identify in heterogeneous
samples using our approach. As described below, the
identification of loss of heterozygosity events is important
for the interpretation of the allelic fraction at somatic
mutations.
Tumors’ mutational landscape
We identified somatic variants, substitutions and inser-
tion/deletions in the sequenced samples using Muta-
scope [10]. Four patients had no mutations, and 34
patients had between one and 12 nonsilent mutations
(one to 16 total mutations). In total, we identified 76
somatic variants across the 34 cases, of which 62 werenonsilent, resulting in a coding change in 28 genes
(Table S6 in Additional file 1).
To highlight the specificities of the patient cohort and
the sequencing assay, we compared our results with
those obtained from a large TCGA cohort of 507 breast
invasive carcinomas that were sequenced at all coding
genes [8]. We observed that 17% of the TCGA samples
had no detectable mutations in the 47 genes of our
panel, as compared with the 10% of samples with no de-
tectable mutations determined by our approach (Figure 3
inset). Similarly, there were three or more somatic muta-
tions in 18% of the samples in our study compared with
only 8% in the TCGA dataset. Thirty-nine of the 41
genes mutated either in our study or in the TCGA dataset
were mutated in the same fraction of samples (P ≥0.05;
Figure 3). Only ERBB2 and PMS2 showed a significant dif-
ference (P <0.05), although the large difference in sample
size could weaken this comparison. Altogether, these
observations suggest our approach has a greater sensi-
tivity to detect mutations in potentially clinically action-
able genes.
The most frequently mutated gene, TP53, was altered in
37% (14/38) of the patients. In six patients, the mutation
Figure 3 Comparison with The Cancer Genome Atlas cohort.
Bar graph representing the fraction of samples with nonsilent
somatic mutations in The Cancer Genome Atlas (TCGA) cohort
(n = 507, blue) and the studied cohort (n = 38, red). *Statistically
significant difference (Fisher test P <0.05). Inset: bar graph indicating
the fraction of samples with none, one, two, or three or more
nonsilent mutations over the entire TCGA cohort (blue) or studied
cohort (red). UDT-Seq, ultra-deep targeted sequencing.
Harismendy et al. Breast Cancer Research 2013, 15:R115 Page 6 of 12
http://breast-cancer-research.com/content/15/6/R115was homozygous, leading to a frameshift (n = 1), a non-
sense (n = 3) or a missense (n = 2), supporting the total
loss of function of TP53 in these cases. In one patient,
three missense mutations (P142L, P158L and R158C)
were present on the same DNA strand, indicating that
one TP53 allele remained wild-type. The remaining seven
patients had heterozygous mutations, which were all pre-
dicted to be deleterious. Interestingly, we noticed TP53
mutations with high allelic fraction in low cellularity tu-
mors (Figure 4A, red box). Assuming that the adjacent tis-
sue sections used for histology and sequencing have
comparable cellularity, this suggests that TP53 mutations
may be present in the surrounding stroma, consistent with
previous observations [16-19].The second most frequently mutated gene, PIK3CA,
was mutated in 24% (9/38) of the patients. All of the
mutations occurred in mutational hotspots known to re-
sult in a phosphoinositide-3 kinase (PI3K) gain of func-
tion: E545K (n = 4), H1047R (n = 3), E542K (n = 1) and
C420R (n = 1) [20]. In contrast to TP53, the allelic frac-
tion of PIK3CA mutants was proportional to the tumor
cellularity (Figure 4B), with the exception of two tumors
(Figure 4B, red box) of high cellularity (>80%) and lower
PIK3CA mutant allelic fraction (<30%), indicating that
the mutations may have been present in only a subset of
the tumor cells.
GATA3 was found mutated in 16% (6/38) of the pa-
tients. Interestingly, five out of the six mutations led to a
frameshift, consistent with the findings of the TCGA
(88%, 38/43) and much higher than the initial GATA3
mutational analysis performed by Sanger sequencing in
breast cancer (30%, 2/6) [21]. The frameshift mutations
in this transcription factor occurred in the vicinity of the
Zn Finger domain (residues 263 to 313), which also sur-
rounds the nuclear localization signal [22]. The mutations
may therefore result in a loss of function by preventing
DNA binding or nuclear import. The unique mutational
profile of GATA3, dominated by frameshift mutations,
may prompt further investigations about their mechanism
of onset and significance.
We also identified less frequently mutated genes with
potential value in the clinic. One patient’s tumor was de-
termined to harbor a PIK3R1-K567E mutation, which has
been observed in endometrial cancer [23]. Although the
significance of this particular substitution is not known,
loss of function mutations of the regulatory subunit of the
PI3K complex can contribute to the activation of PI3K
pathway [24]. Similarly the PTEN frameshift mutation
identified in another patient’s tumor may result in partial
PTEN loss of function and subsequent PI3K activation.
Three patients carried missense mutations in ERBB2, all
predicted to affect its function. Two of these mutations
were located in the kinase domain and are known to me-
diate resistance to lapatinib (L755S) [25] or to activate
Her2 (D769H) [26]. Finally, we identified four mutations
in CDH1 in three tumors. Interestingly, two tumors were
diagnosed as lobular cancer and one had lobular features,
in agreement with the increased prevalence of E-cadherin
loss (encoded by CDH1) in lobular breast cancer [27].
Tumor subclonal populations
While 35/38 patients had between zero and three som-
atic mutations, three patients had more than three mu-
tations. Because of the high sequencing coverage depth
(>1,000-fold), we were able to identify subclonal cell
populations in these tumors (Table S7 in Additional file 1;
Figure 4C). We identified one patient with 12 nonsi-
lent mutations, which corresponds to about 10 times the
Figure 4 Patterns and actionability of somatic mutations. (A), (B) The allelic fraction of all TP53 (A) and PIK3CA (B) nonsilent somatic mutants
(y axis) is displayed as a function of the cellularity of the tumor (x axis). Red boxes indicate samples where the allelic fraction deviates from tumor
cellularity. (C) The allelic fraction of the nonsilent somatic mutations in the three tumors showing evidence of two subclones is displayed as a
function of the tumor cellularity (x axis). Inset: highlighting the distribution of allelic fraction of the mutations identified in the two clones of
AA952. (D) Schematic representation of the type of somatic variation identified in the genes actionable for their somatic status. The tumor
cellularity is displayed in a purple gradient color. The samples are ranked by decreasing number of actionable somatic mutations.
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though this hypermutated tumor had a cellularity of 90%,
we observed a set of seven mutations at 17% and a set of
five mutations at 13% allelic fraction, with both sets repre-
senting statistically different populations (P <10–5, Student’s
t test; Figure 4C, inset). One possible explanation is the
presence of two subclones: assuming the seven mutations
at higher allelic fraction are present in a heterozygous sate
in a major founder clone (28% of the cells, 14% of the
DNA) from which a minor clone arose, adding five het-
erozygous mutations (26% of the cells, 13% of the DNA).
Among the founder clone mutations, we noticed a BRCA1
nonsense mutation, which may explain the high mutation
rate observed in this sample.
The last two patients carried six mutations each. One
patient with lobular carcinoma had two CDH1 muta-
tions and one ERBB2 mutation at ~16% allelic fraction,
as well as a distinct set of mutations in PTEN, BRCA2
and PMS2 at ~5% allelic fraction. The observed allelic
fractions are in contrast with the high cellularity (90%)
and absence of strong rearrangement (SDH = 8.5) in thislobular tumor. Assuming that the mutations are not mu-
tually exclusive, this observation implies that the loss of
a PTEN allele only appeared recently in the tumor and
that the majority of the tumor cells had no detectable
somatic events in the panel of genes investigated. Finally,
the tumor of one patient, also with low SDH and high
cellularity, harbored two hallmark mutations at ~50% al-
lelic fraction (PIK3CA and TP53) probably driving the
initial tumor, but carried four mutations at ~16% allelic
fraction, suggesting the presence of a subclone consist-
ing of 32% of cells. This study highlights how the dif-
ferences in allelic fraction observed within tumors can
reveal subclonal populations and genetic drivers, and
could be used to monitor treatment and possibly prevent
future resistance.
Importance of the germline variants
Our approach identified 586 inherited germline variants,
with a median of 140 per patient, 85% of them present
in dbSNP (Table S8 in Additional file 1 and Additional
file 2). We first investigated the presence of deleterious
Harismendy et al. Breast Cancer Research 2013, 15:R115 Page 8 of 12
http://breast-cancer-research.com/content/15/6/R115variants in BRCA1/2, which are the most actionable
genes in the clinical setting. We identified three patients
with a predicted deleterious mutation in one of these
genes, of which only one seems truly deleterious [28-30]
(Table S9 in Additional file 1). The BRCA1-Q1355_E1356fs
frameshift mutation is a previously reported deleterious
mutation [30] and is clinically actionable. Interestingly,
the mutant allele was selected for in the tumor (allelic
fraction 94%), indicating a selective advantage. This germ-
line finding was later confirmed by a Clinical Laboratory
Improvement Amendments-approved assay after the pa-
tient consulted with a clinical genetic counselor.
Inherited variants in DPYD have been associated with
toxicity to 5-fluorouracil or capecitabine chemotherapy
[12], which is commonly used in breast cancer treat-
ment. We identified six patients carrying three variants
in DPYD with predicted deleterious effects. Three pa-
tients were heterozygous for rs1801160 (Minor Allele
Frequency = 0.04). This single nucleotide polymorphism
defines the DPYD*6 haplotype, which has been associ-
ated with increased toxicity [31]. Two novel missense
variants (K259E and V944A) identified in three patients
have an unknown significance. Interestingly, a recent
study indicates that variants in DPYD can actually in-
crease its metabolic activity, therefore protecting against
toxicity and decreasing drug efficiency [32]. Until more
functional experiments are performed, it will be challen-
ging to unambiguously determine the clinical relevance
of most inherited DPYD variants. We also identified two
patients carrying one inactive allele of the gene
(CYP2D6*6). However, it is not clear whether this particu-
lar allele, in a heterozygous state, is associated with a re-
duced metabolism of tamoxifen; therefore, a change in
drug dosage is not justified.
More generally, our approach identified many inher-
ited variants of unknown significance, which should be
cautiously interpreted. Importantly, in the absence of a
matched germline sample, some of these variants might
have been misidentified as tumor-specific events poten-
tially confounding the rationale for targeted therapy,
therefore highlighting the importance of sequencing
matched germline DNA.
Clinical implications
Out of the 47 genes sequenced, 24 are classified as ac-
tionable based on their somatic status (Table 1). These
genes or the pathway they belong to could be targeted
by a specific inhibitor, commercially available or under
investigation (PIK3CA, ERBB2), or are predictive bio-
markers for targeted therapies that are approved or in
clinical trials (BRCA1/2, PTEN). There were 21 patients
whose tumors carried nonsilent mutations or copy num-
ber alterations in 17 of these 24 genes (Figure 4D). Im-
portantly, three of the patients had tumors with lessthan 20% cellularity and in four patients we identified
mutations at an allelic fraction of 10% or lower. We can
establish the added benefit of our strategy in such cases:
if we had limited our analysis to the samples with cellular-
ity higher than 60% (19 samples), which is the inclusion
criteria used by the TCGA, we would have identified mu-
tations in only six patients for an overall sensitivity of only
31% (6/19 cases). However, by using the UDT-Seq ap-
proach, we identified mutations in actionable genes in 21
of the 38 patients studied for an overall sensitivity of 55%
(21/38 cases), combining the benefits of less stringent in-
clusion criteria and higher assay sensitivity.
Based on these molecular findings, we then summarized
the most likely clinical course of action (Table 2). Looking
at somatic mutations and amplification, we would have
proposed the use of trastuzumab for seven patients based
on ERBB2 status. Notably, for one of them the ERBB2
gene is not amplified but carried an activating mutation,
which would have been missed through standard Her2
testing. We would have further recommended the enroll-
ment of 12 patients in a PIK3CA inhibitor clinical study
due to a mutation in the PIK3/AKT/mTOR pathway. Four
other patients may have been considered as candidates for
the clinical testing of an FGFR inhibitor. Finally, for seven
patients, the molecular testing suggests that they could
each have benefited from PARP, CDK4/6, AKT, ABL2,
BRAF, JAK or RARA inhibitors. Importantly, we were able
to identify 18 patients who might specifically benefit from
the advantages of our approach (Table 2). Regarding
germline mutations, one patient carrying a germline
BRCA1 mutation underwent genetic counseling and had
her mutation confirmed in a Clinical Laboratory Improve-
ment Amendments-certified setting. One patient carried a
germline CFTR deleterious mutation. These types of inci-
dental findings, not related to breast cancer treatment,
should be returned to the patient according to recent
guidelines of the American College of Medical Genetics
[33]. Overall, combining both somatic and germline dis-
coveries, 25 patients had genetic results potentially in-
formative for their care, of which 19 would not have been
identified through routine testing.
Discussion
An increasing number of diagnostic companies and health-
care centers are proposing to perform tumor genetic pro-
filing to support precision cancer care. Assays providing
both deep and genome-wide or broad coverage are not yet
available or currently justified in a clinical setting. There-
fore, one should look directly at patient benefit and clin-
ical utility to select an appropriate strategy. We still have a
limited understanding of the role of most proteins even in
pathways deemed actionable. Therefore, until more clinical
evidence is provided, broad or genome-wide sequencing is
likely to unveil mutations for which a clear therapeutic
Table 2 Summary of the primary course of action likely to result from the molecular testing
Patient SNP or mutation (allelic fraction) Proposed action UDT-Seq advantagesa
AA1025 rs113993959 (Het) CFTR genetic counseling Germline
AA1090 CDKN2A-A85D (66%) CDK4/6 inhibitor
FGFR1 amplification FGFR1/2 inhibitor CNA
AA1106 ERBB2-L755S (17%) Trastuzumab
PTEN-frameshift (5%) PIK3CA inhibitor Depth
BRCA2-I1418T (4%) PARP inhibitor Depth
AA1204b PIK3CA-H1047R (26%) PIK3CA inhibitor Sensitivity
Her2 amplification Trastuzumab CNA
AA1222b Her2 amplification Trastuzumab CNA
AA1247b Her2 amplification Trastuzumab CNA
ERBB2-D769H (5%) Depth
AA1267 PIK3CA-H1047R (45%) PIK3CA inhibitor
AA1277 rs80357508 (Het) BRCA1 genetic counseling Germline
FGFR2 amplification FGFR1/2 inhibitor CNA
AA948 PIK3CA-E545K (34%) PIK3CA inhibitor Sensitivity
AA952 PIK3CA-E545K (16%) PIK3CA inhibitor
BRCA1-W306* (18%) PARP inhibitor
BRCA1-E550K (13%)
JAK2-S131L (16%) JAK inhibitor
JAK3-I386M (13%)
rs1801160 (Het) 5-FU toxicity Germline
AA957 PIK3CA-E542K (28%) PIK3CA inhibitor
AA1515 PIK3CA-E545K (70%) PIK3CA inhibitor
UCI1546879 PIK3R1-K204E (30%) PIK3CA inhibitor
UCI1689380 RARA-337 T (14%) RARA inhibitor
BRAF amplification Vemurafenib
UCI1908503b PIK3CA-H1047R (40%) PIK3CA inhibitor
Her2 amplification Trastuzumab CNA
UCI1951813 PIK3CA-E545K (7%) PIK3CA inhibitor Sensitivity
UCI2076630b Her2 amplification Trastuzumab CNA
UCI2224680 BRCA2-L1829F (2%) PARP inhibitor Depth
UCI2564879 PIK3R1-K204E (30%) PIK3CA inhibitor
UCI2649875 AKT1-L52R (63%) AKT inhibitor
FGFR1 amplification FGFR1/2 inhibitor CNA
UCI4216548 FGFR1-D683H (13%) FGFR1/2 inhibitor
UCI8965412b Her2 amplification Trastuzumab CNA
ABL2 amplification Imatinib CNA
UCI1804937 rs1801160 (Het) 5-FU toxicity Germline
UCI2008866 rs1801160 (Het) 5-FU toxicity Germline
UCI3564897 PIK3CA amplification PIK3CA inhibitor CNA
5-FU, 5-fluorouracil; SNP, single nucleotide polymorphism. aDepth, accurate calls at low allelic fraction (<10%); sensitivity, accurate calls in heterogeneous samples;
CNA, inference of copy number alterations; germline, inclusion of a matched germline DNA. bHer2-positive determined through standard of care.
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trast, the use of deep sequencing of a restricted panel of
genes increases the sensitivity to detect well-known and
actionable mutations, which can have a greater impact in
the clinic. For these reasons, deep sequencing of a re-
stricted gene panel is likely to benefit the greatest number
of patients today. Using our UDT-Seq approach, we iden-
tified potentially actionable mutations in 14/19 patients
whose tumor samples had less than 60% cellularity and
discovered actionable mutations present at 10% allelic
fraction or less in four patients, some of whom had tu-
mors with high malignant cellularity. UDT-Seq offers a
very quantitative measurement of the allelic fraction of
the mutations providing information about the biology of
the tumor. For example, we observed a field effect in tu-
mors harboring TP53 mutations and the presence of sub-
clonal PIK3CA mutations or of multiple mutated clones
in three tumors, probably resulting from their evolution.
Clinical utility of these new data will require specific trials
to show that targeting resistant subclones or field effects
is likely to improve outcomes in both the curative and pal-
liative setting.
Traditionally, tumor-specific markers are investigated
in the tumor specimen only. While this may be sufficient
for protein markers, a DNA mutation is identified as a
mismatch to the reference human genome and could
correspond either to an inherited variant or somatically
acquired mutation in the tumor. Only the sequencing of
matched germline DNA can confirm that the variant is
somatic, providing a better rationale for the use of tar-
geted therapy, or inherited, providing important infor-
mation for the care of the patient and their relatives.
Finally, the use of matched germline DNA sequencing
facilitates the detection of mutations at low allelic frac-
tion [10,34], which, as discussed above, is likely to be ex-
tremely important for optimal implementation in clinical
care. It is typically feasible to obtain a blood or buccal
sample along with the tumor or biopsy sample being in-
vestigated, without excessive burden.
Importantly, the adoption of such transformative diag-
nostic assays in the clinic needs to include physician educa-
tion and training and be associated with the establishment
of molecular tumor boards in academic centers. These mo-
lecular tumor boards are not focused on a particular can-
cer by site of origin, but rather on the molecular markers
identified. The presence of basic scientists with expertise in
the altered pathways also improves the clinical interpret-
ation. Indeed, the role and clinical significance of muta-
tions located in less commonly mutated exons, genes or
in the noncoding portions of the genome [35] remain to
be established. Interpreting these variants of unknown sig-
nificance, whether inherited or somatic, is the most con-
troversial and difficult aspect of clinical sequencing.
Despite attempts to consolidate variants, mutations, andclinical information in public databases, molecular tumor
board members must currently perform extensive litera-
ture searches to predict the impact of a mutation. In our
study, missense mutations in ERBB2 were reported as ac-
tivating by only a few published studies, suggesting their
relevance for trastuzumab or lapatinib treatment. A simi-
lar challenge exists for the interpretation of polymor-
phisms in drug metabolizing genes, which will benefit
from the efforts of the pharmacogenomics research net-
work [36]. Finally, such precision medicine strategy is
sensible only if it benefits the patients. For inherited vari-
ants, access to clinical genetic counseling is critical to in-
terpret the results in the context of a complete family
history. Similarly, targeting genes with somatic mutations
using an investigational drug, requires access to a clinical
trial or reimbursement for off-label use of targeted drugs
with clinical outcome captured in a clinical registry study.
Conclusion
Our study evaluates the potential benefits of the UDT-
Seq of 47 selected genes for breast cancer care. We show
that our assay identifies actionable findings, both inher-
ited variants and somatic mutations, in 25 out of 38
samples. In particular, the specificities of our assay – in-
clusion of germline DNA, identification of copy number
variants, high coverage depth and sensitivity to identify
somatic mutations at low allelic fraction – would have
been directly beneficial to 18 patients. As high-throughput
sequencing starts to be used in clinical care, its establish-
ment as a routine diagnostic assay will require progress on
many fronts: demonstration of technical validity and clin-
ical utility, education of physicians and trainees, and co-
operation with pharmaceutical and insurance companies
to increase drug accessibility.
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